Isolation of coronary progenitor cells from hESC

Funding Type: 
SEED Grant
Grant Number: 
RS1-00295
ICOC Funds Committed: 
$0
Stem Cell Use: 
Embryonic Stem Cell
Public Abstract: 
Coronary artery disease is a leading cause of mortality in the USA, and cannot be cured. Although Stem Cell therapy has been initiated in several cases of cardiovascular dysfunction, all current efforts (including a major clinical trial) are aimed at repairing the myocardial component of the heart. To date, little attention has been dedicated at the potential repair of the damaged coronary vasculature. The goal of this proposal is to lay groundwork for coronary vascular therapy based on embryonic stem cell technology. We hypothesize that human embryonic stem cells have the potential to generate coronary progenitor cells that can be clonally expanded. We also hypothesize that this clonally expanded population will retain the potential to differentiate into the diverse components of the coronary vasculature.
Statement of Benefit to California: 
This proposal investigates new avenues for the cure of coronary artery disease, which is an increasing cause of mortality in the population of California.
Progress Report: 
  • T cells orchestrate immune responses and the ability to generate T cells from embryonic stem cells in a test tube could provide potentially limitless source of customized T cells for a variety of conditions including: cancer, infection and autoimmune diseases. In the past year of CIRM funding we have made progress toward this goal by identifying individual embryonic stem cell lines that have a tendency to give rise to blood cell types, including T cells. We have investigated improvements to the culture system, including manipulating extracellular signals.
  • T cells orchestrate immune responses and the ability to generate T cells from embryonic stem cells in a test tube could provide potentially limitless source of customized T cells for a variety of conditions including: cancer, infection and autoimmune diseases. In the past year of CIRM funding we have made progress toward this goal by comparing different culture conditions and distinct cell lines for their ability to generate blood cell types, including T cells in vitro. In the future, we plan to combine studies in humanized mouse models with in vitro approaches to overcome the bottleneck generating T cells from stem cells.

© 2013 California Institute for Regenerative Medicine